Compare Stocks: SKYE, BRNS, RNAZ, and MDXH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.74	$0.69	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
MDXH MDxHealth	$0.59 +2.0%	$0.63	$0.40 ▼ $5.33	$29.30M	1.68	2.19 million shs	41,781 shs
RNAZ TransCode Therapeutics	$1.85 +8.2%	$2.44	$1.52 ▼ $15.94	$31.57M	1.25	115,664 shs	49,736 shs
SKYE Skye Bioscience	$1.68	$2.44	$1.50 ▼ $14.08	$7.44M	2.86	61,074 shs	14,594 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	0.00%	0.00%	+18.04%	-50.99%
MDXH MDxHealth	-3.22%	+0.75%	-18.64%	+21.95%	-87.16%
RNAZ TransCode Therapeutics	-2.84%	+10.68%	-9.52%	-80.63%	-88.45%
SKYE Skye Bioscience	+1.82%	+5.00%	-10.64%	-69.57%	-87.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.74	$0.69	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
MDXH MDxHealth	$0.59 +2.0%	$0.63	$0.40 ▼ $5.33	$29.30M	1.68	2.19 million shs	41,781 shs
RNAZ TransCode Therapeutics	$1.85 +8.2%	$2.44	$1.52 ▼ $15.94	$31.57M	1.25	115,664 shs	49,736 shs
SKYE Skye Bioscience	$1.68	$2.44	$1.50 ▼ $14.08	$7.44M	2.86	61,074 shs	14,594 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	0.00%	0.00%	+18.04%	-50.99%
MDXH MDxHealth	-3.22%	+0.75%	-18.64%	+21.95%	-87.16%
RNAZ TransCode Therapeutics	-2.84%	+10.68%	-9.52%	-80.63%	-88.45%
SKYE Skye Bioscience	+1.82%	+5.00%	-10.64%	-69.57%	-87.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.47% Upside
MDXH MDxHealth	2.40	Hold	$2.17	265.99% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A
SKYE Skye Bioscience	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SKYE, BRNS, RNAZ, and MDXH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	MDXH MDxHealth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
MDXH MDxHealth	$107.88M	0.27	N/A	N/A	($0.24) per share	-2.47
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$5.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$10.16	N/A	N/A	N/A	N/A	-329.08%	-201.79%	N/A

Latest SKYE, BRNS, RNAZ, and MDXH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	BRNS Barinthus Biotherapeutics	-$0.27	N/A	N/A	N/A	$0.22 million	N/A
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$2.4550	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
MDXH MDxHealth	N/A	1.15	0.98
RNAZ TransCode Therapeutics	N/A	1.97	1.97
SKYE Skye Bioscience	N/A	0.95	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
MDXH MDxHealth	N/A
RNAZ TransCode Therapeutics	N/A
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.50%
MDXH MDxHealth	1.70%
RNAZ TransCode Therapeutics	0.10%
SKYE Skye Bioscience	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
MDXH MDxHealth	364	49.50 million	48.66 million	Not Optionable
RNAZ TransCode Therapeutics	12	16.93 million	16.91 million	Not Optionable
SKYE Skye Bioscience	12	4.43 million	4.15 million	Optionable

SKYE, BRNS, RNAZ, and MDXH Headlines

Recent News About These Companies

Il direttore di Skye Bioscience Andrew Schwab vende azioni per $239.555

September 25, 2026 | it.investing.com

Skye Bioscience (NASDAQ:SKYE) Stock: Insider Andrew Schwab Sells 28,700 Shares

September 25, 2026 | insidertrades.com

5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock

September 19, 2026 | insidertrades.com

Skye Bioscience average analyst price target raised 10.29% to $61.20

September 15, 2026 | msn.com

Skye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the move

August 26, 2026 | msn.com

Skye Bioscience (NASDAQ:SKYE) Director Sells 68,140 Shares

August 21, 2026 | insidertrades.com

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

August 14, 2026 | seekingalpha.com

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

August 14, 2026 | globenewswire.com

Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE

July 12, 2026 | natlawreview.comN

Cadrenal Therapeutics Names Sharp Interim CFO

June 29, 2026 | marketwatch.com

Skye Bioscience Expands Authorized Shares After Shareholder Approval

May 29, 2026 | tipranks.com

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026 | globenewswire.com

Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87

May 14, 2026 | msn.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

May 14, 2026 | theglobeandmail.com

Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 14, 2026 | finanznachrichten.de

Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE

May 13, 2026 | natlawreview.comN

Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026

May 12, 2026 | quiverquant.comQ

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026 | globenewswire.com

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026 | globenewswire.com

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

April 22, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, BRNS, RNAZ, and MDXH Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 10/8/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

MDxHealth NASDAQ:MDXH

$0.59 +0.01 (+1.98%)

As of 03:07 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

TransCode Therapeutics NASDAQ:RNAZ

$1.85 +0.14 (+8.19%)

As of 03:08 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Skye Bioscience NASDAQ:SKYE

$1.68 0.00 (0.00%)

As of 03:10 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SKYE, BRNS, RNAZ, and MDXH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SKYE, BRNS, RNAZ, and MDXH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SKYE, BRNS, RNAZ, and MDXH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, BRNS, RNAZ, and MDXH Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

MDxHealth NASDAQ:MDXH

TransCode Therapeutics NASDAQ:RNAZ

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SKYE, BRNS, RNAZ, and MDXH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SKYE, BRNS, RNAZ, and MDXH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SKYE, BRNS, RNAZ, and MDXH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, BRNS, RNAZ, and MDXH Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

MDxHealth NASDAQ:MDXH

TransCode Therapeutics NASDAQ:RNAZ

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools